Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

1.02

Mkt cap

6.9M

Volume

193K

High

1.09

P/E Ratio

-0.27

52-wk high

4.17

Low

1.00

Div yield

N/A

52-wk low

0.77

On Wednesday, U.S. stock indexes closed lower, with notable movements in specific stocks. MicroStrategy Inc. saw an 8.67% increase, attributed to Bitcoin's surge affecting its shares and bonds. Adial Pharmaceuticals Inc. jumped 106.19% after publishing positive clinical results for AD04. Alpine Immune Sciences Inc. rose 20.80%, exploring strategic options including a sale. Marin Software Inc. surged 126.30% following upgrades to its Microsoft advertising integration. Tesla Inc. dropped 2.89% amid potential talks between its CEO and the Indian Prime Minister.

Portfolio Pulse from Benzinga Neuro

April 11, 2024 | 2:19 am

In Wednesday's after-market session, health care stocks saw significant movement. Rallybio, Vera Therapeutics, and Biophytis were among the top gainers, with Rallybio leading at a 31.9% increase. On the downside, CytomX Therapeutics, Orgenesis, and OneMedNet were the major losers, with CytomX Therapeutics experiencing a 7.2% drop. These movements reflect the volatile nature of health care stocks in the market.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 8:31 pm

U.S. stocks declined, with the S&P 500 down 1%. Delta Air Lines reported better-than-expected Q1 earnings, with an 8% revenue growth. Energy shares rose by 0.3%, while real estate shares fell by 4.3%. Marin Software, Adial Pharmaceuticals, and Jaguar Health saw significant stock increases, whereas VIA optronics, Ascent Solar Technologies, and Velo3D experienced notable declines.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 6:34 pm

Ascent Solar Technologies, Inc. (ASTI) shares fell by 50% after announcing a $6 million public offering at $0.14 per share. Other stocks experienced significant movements, with Marin Software (MRIN) and Adial Pharmaceuticals (ADIL) among the top gainers, while VIA optronics (VIAO) and Velo3D, Inc. (VLD) led the losers.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 6:07 pm

In Wednesday's intraday session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals led the gainers with a 61.6% increase, while Acorda Therapeutics headed the losers with a 20.4% decrease. Other notable movers included Jaguar Health, Orgenesis, BioSig Technologies, and Telomir Pharmaceuticals on the gainers' side, and Kineta, DocGo, Biophytis, Yield10 Bioscience, and Eyenovia among the losers.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 4:31 pm

U.S. stocks traded lower, with the Dow Jones index falling over 500 points. Energy shares fell by 0.3%, while real estate shares tumbled by 4.1%. U.S. crude oil inventories increased more than expected. Marin Software's shares jumped 146% after announcing upgrades with Microsoft Advertising. Adial Pharmaceuticals surged 66% following a positive article on AD04. Jaguar Health gained 37% after a successful stockholder meeting. VIA optronics, Ascent Solar Technologies, and Velo3D saw significant drops after various announcements.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 4:15 pm

Adial Pharmaceuticals (ADIL) shares surged 108% following the publication of a peer-reviewed article on AD04's clinical results and safety. Nano Labs (NA) filed its annual report, showing a 70% increase. ABVC BioPharma (ABVC) announced a global licensing agreement for oncology/hematology products, expecting $55M in licensing income and up to $50M in royalties.

Portfolio Pulse from ryanfaloona@benzinga.com

April 10, 2024 | 12:39 pm

Adial Pharmaceuticals' stock is trading higher following the announcement of a peer-reviewed article publication. The article emphasizes the clinical results, strong safety profile, and high compliance of patients treated with AD04.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:30 pm

In Wednesday's pre-market session, several healthcare stocks showed significant movement. IN8bio, Jaguar Health, China SXT Pharmaceuticals, Adial Pharmaceuticals, iSpecimen, and Akebia Therapeutics were among the gainers, with increases ranging from 11.03% to 47.7%. Conversely, BioSig Technologies, Cocrystal Pharma, Synaptogenix, Kineta, Biophytis, and Addex Therapeutics experienced declines between 6.42% and 13.0%.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 12:09 pm

Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced positive clinical results for AD04, its lead investigational drug for Alcohol Use Disorder (AUD), showing a strong safety profile, high patient compliance, and no significant adverse effects. The study compared AD04's liver safety profile to a placebo in subjects with AUD, revealing no significant changes in liver injury markers. Additionally, ADIL received a U.S. patent in February for AD04 targeting the serotonin transporter gene for opioid use disorder treatment.

Portfolio Pulse from Vandana Singh

April 10, 2024 | 12:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.